Border to Coast Pensions Partnership Ltd elevated its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 4.5% through the third quarter, Holdings Channel.com experiences. The agency owned 260,931 shares of the corporate’s inventory after buying an extra 11,131 shares through the quarter. Border to Coast Pensions Partnership Ltd’s holdings in Johnson & Johnson have been value $42,163,000 as of its most up-to-date submitting with the SEC.
A number of different institutional traders and hedge funds additionally not too long ago purchased and bought shares of JNJ. Marshall Wace LLP boosted its place in shares of Johnson & Johnson by 506.9% within the second quarter. Marshall Wace LLP now owns 3,884,962 shares of the corporate’s inventory value $567,826,000 after buying an extra 3,244,862 shares through the interval. Worth T Rowe Associates Inc. MD elevated its stake in Johnson & Johnson by 16.8% within the 1st quarter. Worth T Rowe Associates Inc. MD now owns 21,834,359 shares of the corporate’s inventory value $3,453,978,000 after shopping for an extra 3,139,499 shares within the final quarter. Ninety One UK Ltd raised its stake in Johnson & Johnson by 59.0% through the 2nd quarter. Ninety One UK Ltd now owns 6,708,943 shares of the corporate’s inventory valued at $980,579,000 after buying an extra 2,489,925 shares through the interval. Swedbank AB purchased a brand new place in shares of Johnson & Johnson through the first quarter value $331,178,000. Lastly, Massachusetts Monetary Providers Co. MA grew its place in shares of Johnson & Johnson by 10.8% through the second quarter. Massachusetts Monetary Providers Co. MA now owns 18,780,645 shares of the corporate’s inventory valued at $2,744,979,000 after buying an extra 1,831,751 shares within the final quarter. 69.55% of the inventory is presently owned by hedge funds and different institutional traders.
Johnson & Johnson Buying and selling Down 1.4 %
Shares of NYSE JNJ opened at $162.85 on Tuesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month excessive of $168.85. The corporate has a fast ratio of 0.85, a present ratio of 1.07 and a debt-to-equity ratio of 0.44. The enterprise has a fifty day easy transferring common of $163.04 and a two-hundred day easy transferring common of $154.77. The agency has a market cap of $391.92 billion, a PE ratio of 10.15, a price-to-earnings-growth ratio of two.65 and a beta of 0.52.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final issued its earnings outcomes on Tuesday, October fifteenth. The corporate reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a web margin of 46.34% and a return on fairness of 36.60%. The corporate had income of $22.47 billion for the quarter, in comparison with analysts’ expectations of $22.17 billion. Throughout the identical interval within the prior yr, the enterprise earned $2.66 EPS. The agency’s quarterly income was up 5.2% on a year-over-year foundation. Analysts anticipate that Johnson & Johnson will put up 10 earnings per share for the present fiscal yr.
Johnson & Johnson Broadcasts Dividend
The enterprise additionally not too long ago introduced a quarterly dividend, which will probably be paid on Tuesday, December tenth. Shareholders of document on Tuesday, November twenty sixth will probably be issued a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November twenty sixth. This represents a $4.96 dividend on an annualized foundation and a yield of three.05%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.
Insider Shopping for and Promoting at Johnson & Johnson
In associated information, VP Robert J. Decker bought 5,635 shares of the corporate’s inventory in a transaction on Friday, August thirtieth. The inventory was bought at a median value of $165.06, for a complete transaction of $930,113.10. Following the completion of the sale, the vice chairman now straight owns 18,973 shares within the firm, valued at $3,131,683.38. This represents a 0.00 % lower of their place. The sale was disclosed in a doc filed with the SEC, which is out there by this hyperlink. Insiders personal 0.16% of the corporate’s inventory.
Analyst Rankings Adjustments
Quite a few analysis corporations not too long ago issued experiences on JNJ. Wells Fargo & Firm upped their value goal on shares of Johnson & Johnson from $163.00 to $166.00 and gave the corporate an “equal weight” ranking in a analysis word on Wednesday, October sixteenth. TD Cowen lowered their value goal on shares of Johnson & Johnson from $195.00 to $185.00 and set a “purchase” ranking for the corporate in a report on Thursday, July 18th. The Goldman Sachs Group decreased their value goal on Johnson & Johnson from $160.00 to $155.00 and set a “impartial” ranking on the inventory in a analysis word on Friday, July nineteenth. Royal Financial institution of Canada lifted their goal value on Johnson & Johnson from $178.00 to $181.00 and gave the inventory an “outperform” ranking in a report on Wednesday, October sixteenth. Lastly, StockNews.com upgraded Johnson & Johnson from a “purchase” ranking to a “strong-buy” ranking in a report on Saturday, September 14th. Six analysts have rated the inventory with a maintain ranking, seven have issued a purchase ranking and one has given a powerful purchase ranking to the inventory. Based on information from MarketBeat.com, Johnson & Johnson has a median ranking of “Average Purchase” and a consensus value goal of $175.93.
View Our Newest Report on Johnson & Johnson
About Johnson & Johnson
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells varied merchandise within the healthcare area worldwide. The corporate’s Progressive Drugs section provides merchandise for varied therapeutic areas, similar to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious ailments comprising HIV/AIDS; neuroscience, consisting of temper problems, neurodegenerative problems, and schizophrenia; oncology, similar to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Additional Studying
Need to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Rankings for Johnson & Johnson Every day – Enter your e-mail handle beneath to obtain a concise day by day abstract of the most recent information and analysts’ rankings for Johnson & Johnson and associated firms with MarketBeat.com’s FREE day by day e-mail publication.
